On June 20th, Gilead Science announced that the top line results of the mid-term analysis of the critical Phase 3 PURPOSE 1 clinical trial showed that the twice administered injection of the HIV-1 capsid inhibitor lenacapavir (lenacapavir) demonstrated 100% effectiveness in HIV prevention studies targeting cisgender women.
According to 21st Century Business Herald reporters, this project is the most comprehensive and diverse HIV prevention clinical trial project to date.
On June 24, the share price of A-share AIDS drug listed companies fell sharply. As of the closing, Aidi Pharmaceutical fell more than 14%, and Frontier Biology fell more than 6%.
In this regard, the reporter of Nancai Express called Aidi Pharmaceutical as an investor, and relevant people said that Gilead Science did AIDS prevention for high-risk exposed groups in advance, while the company provided drugs for clinical trials of AIDS patients. When asked whether there will be no AIDS patients in the future, the above people said that according to the current test results, it may do some prevention, but there are still a large number of patients in stock who need medication.
The reporter also called Frontier Biology, but was not connected.